Continuous dopamine-receptor stimulation in early Parkinson's disease

Trends in Neurosciences

Volumn 23, Issue 10 SUPPL., 2000, Pages

  Olanow, C Warren ^a   Schapira, Anthony H V ^b   Rascol, Olivier ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

DRUG EFFECT; HUMAN; MONKEY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0033695789     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-1931(00)00030-6     Document Type: Review

References (74)

1. Parkinson's disease
2. Drug therapy: Treatment of Parkinson's disease
3. A multi-center, double-blind, placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease
4. Effect of peripheral catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics and pharmacodynamics of L-dopa in parkinsonian patients
5. Entacapone improves motor fluctuations in L-dopa-treated Parkinson's disease patients
6. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations
7. Preventing levodopa-induced dyskinesia
8. The functional anatomy of basal ganglia disorders
9. Primate models of movement disorders of basal ganglia origin
10. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated
11. Opposing modulation of cortical NMDA receptor-mediated responses by low and high concentrations of dopamine
12. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism
13. Regional brain uptake of 2-deoxy glucose in MPTP-induced parkinsonism in the Macaque monkey
14. Metabolic topography of parkinsonism
15. Pathophysiology of the basal ganglia in Parkinson's disease
16. Single striatofugal axons arborizing in both pallidal segments and in the substantia nigra in primates
17. Single-axon tracing study of neurons of the external segment of the globus pallidus in primate
18. Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons
19. Alterations in electrophysiological activity and dye coupling of striatal spiny and aspiny neurons in dopamine-denervated rat striatum recorded in vivo
20. Dye coupling between rat striatal neurons recorded in vivo: Compartmental organization and modulation by dopamine
21. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus
22. Alleviation of parkinsonism by antagonist of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate
23. Posteroventral medial pallidotomy in advanced Parkinson's disease
24. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease
25. Surgery for Parkinson's disease: A physician's perspective
26. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: Problems with current models of the basal ganglia
27. Excitotoxic acid lesions of the primate subthalamic nucleus result in reduced pallidal neuronal activity during active holding
28. Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum
29. Effects of apomorphine on globus pallidus neurons in Parkinsonian patients
30. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia
31. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications
32. The neuronal network of the basal ganglia as revealed by the study of synaptic connections of identified neurons
33. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys
34. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
35. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia
36. Predictive reward signal of dopamine neurons
37. Continuous and intermittent levodopa differentially affect basal ganglia function
38. Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys
39. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys
40. Dyskinesia and wearing-off following dopamine D1 treatment in drug-naive 1-methyl-4-phenyl-1,2,3,-6-tetrahydropyridine-lesioned primates
41. 3H] spiperone binding
42. Behavioral and biochemical effect of chronic treatment with D1 and/or D2 dopamine agonists in MPTP monkeys
43. Effect of chronic treatment of MPTP monkeys with dopamine D1 and/or D2 receptor agonists
44. Dopamine D1 receptor mRNA and receptor levels in striatum of MPTP monkeys chronically treated with SKF-82958
45. De novo administration of ropinirole and bromocriptine induces less dyskinesia than levodopa in MPTP-treated marmoset
46. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys
47. Dopamine D1 receptor mRNA and receptor levels in striatum of MPTP monkeys chronically treated with SKF-82958
48. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive, 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: In situ hybridization histochemical analysis
49. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: Comparison with L-dopa therapy
50. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists
51. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum
52. Dopamine receptors: From structure to behavior
53. Treatment of Parkinson's disease with L-dopa and R-4602: Review and present status
54. Chronic parkinsonism in humans due to a product of meperidine analog synthesis
55. The response to levodopa in Parkinson's disease: Imposing pharmacologic law and order
56. L-dopa and dyskinesias in normal monkeys
57. A randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease: A five year follow-up
58. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: A 5-year follow-up
59. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
60. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group
61. Pramipexole versus levodopa in early Parkinson's disease: The randomized controlled CALM-PD trial
62. Pergolide vs L-dopa (PELMOPET)
63. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates
64. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltrasferase inhibitor tolcapone during first administration to humans
65. Inhibition of catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone
66. 18F-6-L-fluorodopa metabolism: Implications for levodopa therapy in Parkinson's disease
67. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations
68. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations
69. Tolcapone improves motor function in parkinsonian patients with the 'wearing off' phenomenon: A double-blind, placebo-controlled, multicenter trial
70. Entacapone improved motor fluctuations in levodopa-treated Parkinson's disease patients
71. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations
72. Tolcapone (tasmar) and hepatotoxicity
73. COMT inhibition in Parkinson's disease
74. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: Implications for the early use of COMT inhibitors